TerrAscend Corp.

TSX:TSND.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$0.52 -1.61%

-$0.02 today

Market cap
$193.65M
Beta
2.04
P/E (TTM)
-2.5
EPS (TTM)
-$0.26
52W Low $0.33High $2.00

Volume 0.26M

Average 0.31M

TSND.TO Common Stock Repurchased

Cash spent buying back the company's own shares.

TerrAscend Corp.TSX: TSND.TO

Common Stock Repurchased · Q1 FY2026 · quarter ended Mar 2026

Common stock repurchased declines year over year

Q1 FY2026 common stock repurchased of $75.74K (cash outflow) fell 67.2% year over year, behind the -42.8% change in trailing-twelve-month common stock repurchased. Sequentially, it rose 127.4% from the prior quarter.

Context

  • Common stock repurchased amounted to 0.2% of revenue in FY2025, unchanged from a year earlier.
  • Common stock repurchased increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -67.2% toward the trailing-twelve-month pace of -42.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$75.74K+127.4% QoQ
Last fiscal yearDec 2025
-$417.18K+94.0% YoY
LTMMar 2026
-$255.04K-42.8% YoY
Common Stock Repurchased past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-67.2%——
1 year+94.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Common Stock Repurchased history

USD · from the cash flow

Latest · FY2025
(417.18K) USD
Year-over-year change
-94.0%

Common Stock Repurchased vs competitors

How TSND.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock repurchased is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -42.8% is the 4th highest of 5, against a peer median of +162.2%.
  • Common stock repurchased amounts to 0.1% of revenue for TSND.TO, versus a peer median of 0.0%.
TSND.TO Competitors
Common Stock Repurchased for TSND.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DR.TOMedical Facilities CorporationLTM Mar 2026$23.44M USD-61.3%+19.1%7.7%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$5.41M USD+314580.5%+40.2%10.6%
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$1.62M USD+224.4%+22.4%2.9%
TSND.TOTerrAscend Corp.LTM Mar 2026$255.04K USD-42.8%—0.1%
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026$0 USD———
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$0 USD+100.0%—0.0%
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$0 CAD——0.0%
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$0 CAD——0.0%
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$0 CAD——0.0%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$0 CAD——0.0%
Peer median (excluding TSND.TO) —+162.2%+22.4%0.0%

Competitors are the stored peer set for TSND.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(21.82M)22.61M(27.63M)(72.67M)(24.49M)
Depreciation & Amortization13.63M23.87M30.64M22.99M17.51M
Deferred Income Tax(1.81M)(46.02M)(18.92M)(8.75M)(532K)
Stock-Based Compensation14.93M12.18M7.71M9.71M5.01M
Change in Working Capital(45.17M)37.81K35.67M28.84M23.24M
Accounts Receivables(4.02M)3.73M(12.5M)(2.95M)1.67M
Inventory(23.19M)881.27K(7M)4.17M6.05M
Accounts Payables3.53M(15.78M)869.2K(5.29M)(4.59M)
Other Working Capital(21.49M)11.2M52.07M32.91M20.11M
Other Non-Cash Items(4.62K)(38.8M)(2.42K)57.84M1.34M
Operating Cash Flow(38.43M)(33.38M)27.47M37.95M22.07M
Capital Expenditures(50.39M)(54.61M)(9.43M)(10.55M)(8.76M)
Acquisitions (Net)(53.55M)19.77M(16.79M)(250K)(8.68M)
Purchases of Investments(62.65M)0000
Sales of Investments00000
Other Investing Activities34.17M7.27M5.44M(2.64M)3.16M
Investing Cash Flow(132.42M)(27.58M)(16.22M)(12.25M)(15.03M)
Debt Repayment(3.67M)54.4K(27.76M)(17.18M)8.36M
Common Stock Issued200.83M23.62M20.82M00
Common Stock Repurchased000(215K)(417.18K)
Dividends Paid00000
Other Financing Activities(14.96M)(19.95M)(5.56M)(7.32M)(3.69M)
Financing Cash Flow182.2M3.72M(12.5M)(24.72M)4.26M
Effect of Forex Changes2.45M(2.9M)(168K)653K(2.11M)
Net Change in Cash20.42M(52.88M)(1.42M)1.64M9.19M
Free Cash Flow(88.82M)(88M)18.04M27.4M13.31M

TerrAscend Corp.

TSX:TSND.TO

Intrinsic Alpha fair value

Locked

Current Price

$0.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.